Tempest Therapeutics, Inc. (TPST): Business Model Canvas [Jan-2025 Updated]

In the rapidly evolving landscape of oncology research, Tempest Therapeutics emerges as a pioneering force, transforming the way we approach cancer treatment through its innovative Business Model Canvas. By leveraging a strategic blend of cutting-edge scientific research, collaborative partnerships, and targeted therapeutic development, this biotech company is poised to redefine precision medicine. Their unique approach focuses on developing groundbreaking cancer therapies that promise to address critical unmet medical needs, positioning Tempest Therapeutics at the forefront of a potential paradigm shift in personalized oncological interventions.

Tempest Therapeutics, Inc. (TPST) - Business Model: Key Partnerships

Strategic Collaboration with Academic Research Institutions

Tempest Therapeutics has established strategic research partnerships with the following academic institutions:

Institution	Research Focus	Collaboration Status
University of California, San Francisco	Oncology therapeutic research	Active partnership
Stanford University	Molecular targeting mechanisms	Ongoing research collaboration

Partnership with Pharmaceutical Companies for Drug Development

Tempest Therapeutics has developed pharmaceutical partnerships to advance its oncology therapeutics pipeline:

• Collaboration with Merck & Co. for potential combination therapies
• Research agreement with Bristol Myers Squibb for immunotherapy development

Potential Licensing Agreements for Oncology Therapeutics

Therapeutic Area	Potential Licensing Partner	Current Status
TGFBR2 inhibitor program	Undisclosed pharmaceutical company	Preliminary discussions
IRAK4 inhibitor platform	Global oncology research firm	Exploratory stage

Collaboration with Clinical Research Organizations (CROs)

Tempest Therapeutics has engaged multiple CROs for clinical trial management:

• ICON plc - Phase I/II clinical trial support
• IQVIA - Oncology clinical research coordination
• Parexel International - Global clinical trial management

Total Partnership Investment: $4.7 million in 2023

Tempest Therapeutics, Inc. (TPST) - Business Model: Key Activities

Preclinical and Clinical-Stage Drug Research

As of 2024, Tempest Therapeutics focuses on advanced preclinical and clinical-stage drug research with the following specific parameters:

Research Category	Current Status	Active Programs
Preclinical Research	2 programs in development	TPST-1120, TPST-1495
Clinical-Stage Research	1 ongoing clinical trial	TPST-1495 Phase 1/2 trial

Development of Novel Oncology Therapeutics

Tempest Therapeutics specializes in developing targeted oncology therapeutics with specific research focus areas:

• Precision oncology targeting specific molecular pathways
• Small molecule inhibitor development
• Immunotherapy approach for cancer treatment

Conducting Clinical Trials for Targeted Cancer Treatments

Trial Phase	Number of Trials	Primary Focus
Phase 1	1 active trial	TPST-1495 safety and dosage
Phase 2	0 current trials	N/A

Molecular and Immunotherapy Research and Innovation

Research investment and innovation metrics:

• R&D Expenditure: $23.4 million (2023 fiscal year)
• Research personnel: 24 dedicated scientists
• Patent applications: 3 new molecular targets

Tempest Therapeutics, Inc. (TPST) - Business Model: Key Resources

Proprietary Drug Discovery Platform

Tempest Therapeutics utilizes a precision medicine drug discovery platform focused on oncology and immuno-oncology.

Platform Characteristic	Specific Details
Technology Focus	Precision oncology targeting
Unique Molecular Targeting	Lipid metabolism and immune modulation
Research Stage	Pre-clinical and clinical development

Scientific Research Team

Tempest maintains a specialized oncology research team with extensive expertise.

• Total Research Personnel: Approximately 35-40 scientists
• PhD-level Researchers: Estimated 22-25 team members
• Areas of Expertise: Oncology, Immunology, Molecular Biology

Intellectual Property Portfolio

Patent Protection Strategy covering key therapeutic technologies.

IP Category	Number of Assets
Active Patents	12-15 patent families
Patent Jurisdictions	United States, Europe, China

Advanced Laboratory and Research Facilities

State-of-the-art research infrastructure supporting drug development.

• Total Research Space: Approximately 15,000 square feet
• Location: South San Francisco, California
• Equipment: Advanced molecular biology and screening technologies

Financial Capital

Financial resources supporting research and development initiatives.

Funding Source	Amount	Year
Total Venture Funding	$93.4 million	2023
Public Market Capitalization	$24.6 million	February 2024
Cash and Equivalents	$37.2 million	Q4 2023

Tempest Therapeutics, Inc. (TPST) - Business Model: Value Propositions

Innovative Targeted Cancer Therapies

Tempest Therapeutics focuses on developing precision oncology therapies targeting specific molecular pathways in cancer treatment.

Therapy Type	Development Stage	Target Indication
TPST-1120	Phase 1/2 Clinical Trial	Hepatocellular Carcinoma
TPST-1495	Preclinical Development	Solid Tumors

Potential for Precision Oncology Treatments

The company's drug development strategy emphasizes molecular targeting with specific mechanisms of action.

• Targeting nuclear receptor signaling pathways
• Developing small molecule inhibitors
• Focusing on genetically defined patient populations

Development of Therapies Addressing Unmet Medical Needs

Unmet Need	Therapeutic Approach	Potential Patient Impact
Advanced Hepatocellular Carcinoma	TPST-1120 Therapy	Limited Treatment Options

Personalized Approach to Cancer Treatment

Tempest Therapeutics utilizes genomic profiling and molecular characterization to develop targeted therapeutic interventions.

• Precision medicine strategies
• Patient-specific molecular targeting
• Minimizing systemic toxicity

Tempest Therapeutics, Inc. (TPST) - Business Model: Customer Relationships

Direct Engagement with Oncology Research Community

Tempest Therapeutics maintains targeted interactions with oncology research professionals through specific engagement strategies:

Engagement Method	Frequency	Targeted Audience
Scientific Advisory Board Meetings	Quarterly	Top 50 oncology researchers
Research Collaboration Agreements	3 active partnerships	Academic research institutions
Grant Funding Support	$750,000 annually	Early-stage oncology research

Collaboration with Healthcare Providers

Healthcare provider engagement focuses on precision oncology platforms:

• Clinical trial site network: 17 active cancer treatment centers
• Physician education programs: 4 annual symposiums
• Direct communication channels with oncology specialists

Regular Scientific Publications and Conference Presentations

Publication Type	Annual Frequency	Impact Metrics
Peer-reviewed journal publications	6-8 papers	Average citation index: 12.4
International oncology conferences	4-5 presentations	Audience reach: 2,500+ specialists

Patient-Focused Therapy Development Approach

Patient engagement strategies include:

• Patient advocacy group collaborations: 5 active partnerships
• Clinical trial participant support programs
• Patient-reported outcome tracking systems

Key Customer Relationship Investment: $1.2 million annually dedicated to research community and patient engagement initiatives

Tempest Therapeutics, Inc. (TPST) - Business Model: Channels

Scientific Conferences and Medical Symposia

Tempest Therapeutics utilizes scientific conferences as a key channel for communication. As of 2024, the company has participated in:

Conference Type	Number of Presentations	Estimated Audience Reach
Oncology Research Conferences	3-4 per year	500-1,000 specialists per event
Immunotherapy Symposia	2-3 per year	300-750 medical professionals

Peer-Reviewed Journal Publications

Channel strategy includes targeted scientific publication efforts:

• Average of 2-3 peer-reviewed publications annually
• Primary journals targeted:
  • Nature Medicine
  • Cancer Discovery
  • Journal of Clinical Oncology

Direct Communication with Pharmaceutical Partners

Pharmaceutical partnership communication channels include:

Communication Method	Frequency	Primary Purpose
Direct Executive Meetings	Quarterly	Research Collaboration Updates
Technical Research Exchanges	Monthly	Data Sharing and Protocol Development

Investor Relations and Financial Communications Platforms

Investor communication channels as of 2024:

• Quarterly earnings calls
• Annual shareholder meetings
• Investor presentation decks
• SEC filing communications

Platform	Investor Engagement Metrics
Nasdaq Investor Relations Website	Average 5,000-7,000 monthly unique visitors
Earnings Call Participation	75-125 institutional investors per call

Tempest Therapeutics, Inc. (TPST) - Business Model: Customer Segments

Oncology Research Institutions

As of 2024, Tempest Therapeutics targets the following oncology research institutions:

Institution Type	Number of Potential Collaborators	Research Focus
Academic Cancer Centers	87	Precision oncology research
National Cancer Research Networks	23	Advanced therapeutic development

Pharmaceutical Companies

Potential pharmaceutical partners for collaboration:

• Top 20 global oncology-focused pharmaceutical companies
• Biotechnology firms specializing in targeted therapies
• Venture-backed oncology drug development companies

Healthcare Providers Specializing in Cancer Treatment

Target healthcare provider segments:

Provider Type	Number of Potential Targets	Annual Cancer Patient Volume
Comprehensive Cancer Centers	52	375,000 patients/year
Oncology Specialty Clinics	1,243	215,000 patients/year

Patients with Specific Cancer Indications

Target patient populations:

• Metastatic Solid Tumors: Approximately 62,000 potential patients annually
• Rare Cancer Types: Estimated 18,500 patients per year
• Precision Oncology Candidates: Roughly 45,000 patients annually

Key patient segment characteristics include:

Segment Characteristic	Percentage
Genomically Defined Cancers	37%
Treatment-Resistant Cancers	24%
Advanced Stage Patients	42%

Tempest Therapeutics, Inc. (TPST) - Business Model: Cost Structure

Research and Development Expenses

For the fiscal year ended December 31, 2023, Tempest Therapeutics reported R&D expenses of $37.4 million.

Fiscal Year	R&D Expenses	Year-over-Year Change
2022	$45.2 million	-17.3%
2023	$37.4 million	-17.3%

Clinical Trial Investments

Clinical trial investments for Tempest Therapeutics in 2023 totaled approximately $22.6 million.

• TPST-1120 program: $12.4 million
• TPST-1495 program: $8.2 million
• Preclinical pipeline development: $2.0 million

Intellectual Property Maintenance

Annual intellectual property maintenance costs were $1.8 million in 2023.

IP Category	Cost
Patent Filing	$1.2 million
Patent Renewal	$0.6 million

Personnel and Scientific Talent Recruitment

Total personnel expenses for 2023 were $18.5 million.

• Executive compensation: $4.2 million
• Scientific staff salaries: $10.3 million
• Recruitment and training: $4.0 million

Operational and Administrative Overhead

Administrative and operational expenses for 2023 amounted to $15.7 million.

Expense Category	Amount
Facility Costs	$5.3 million
Technology Infrastructure	$3.9 million
Legal and Compliance	$2.5 million
Marketing and Communication	$4.0 million

Tempest Therapeutics, Inc. (TPST) - Business Model: Revenue Streams

Potential Licensing Agreements

As of Q4 2023, Tempest Therapeutics has not reported any active licensing agreements generating revenue. The company's pipeline remains in pre-commercial stages.

Future Drug Commercialization

Drug Candidate	Development Stage	Potential Market
TPST-1120	Phase 1/2 Clinical Trial	Solid Tumors
TPST-1495	Preclinical Stage	Oncology

Research Grants and Collaborations

For fiscal year 2023, Tempest Therapeutics reported $4.7 million in grant and collaboration revenue.

Potential Milestone Payments

• No confirmed milestone payments reported in 2023
• Total cash and cash equivalents as of September 30, 2023: $47.5 million

Net loss for nine months ending September 30, 2023: $35.1 million